악성중피종 시장 : 약제 유형, 치료 유형, 투여 경로, 유통별 - 세계 예측(2025-2030년)

The Malignant Mesothelioma Market was valued at USD 772.67 million in 2023, expected to reach USD 834.43 million in 2024, and is projected to grow at a CAGR of 8.26%, to USD 1,347.15 million by 2030.

Malignant Mesothelioma, a rare and aggressive type of cancer associated predominantly with asbestos exposure, is being extensively studied within the market research realm to ascertain its market scope and definition. This condition necessitates ongoing research for effective treatments and preventative strategies due to its poor prognosis. The market includes applications in pharmaceutical developments, diagnostic advancements, and therapeutic procedures aimed at improving patient outcomes. Key end-users comprise healthcare providers, research institutions, and pharmaceutical companies. Market growth is primarily influenced by increasing awareness and stringent regulatory frameworks for asbestos use, coupled with advances in medical research and technology. However, challenges such as the high cost of treatment, limited early diagnosis, and a relatively small patient population hinder the market expansion. Latest opportunities lie in innovative immunotherapy and gene therapy developments which are gaining traction. Strategic collaborations between biotechnology firms and healthcare organizations are paramount to fast-tracking clinical trials and market entry for new treatments. Additionally, personalized medicine based on genetic profiling could revolutionize the management of the disease, offering tailored treatment for better efficacy. Despite significant research investments, limitations persist in the form of resistance to current treatments and the complexity of disease mechanisms. This necessitates continued exploration into novel therapeutic avenues and molecular research. The nature of the mesothelioma market appears to be highly specialized and competitive, driven by the urgent need for breakthrough treatments and efficient diagnostic solutions. Innovations that could lead to early detection, cost-effective therapies, and improved patient care pathways stand to significantly impact the market landscape. Stakeholders should focus on fostering partnerships and leveraging technological advancements such as artificial intelligence and machine learning to enhance diagnostic precision and treatment personalization.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Malignant Mesothelioma Market

The Malignant Mesothelioma Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidence of malignant mesothelioma worldwide
  • Increase in the number of clinical trials for the treatment of malignant mesothelioma
  • Use of diagnostic and prognostic biomarkers for malignant mesothelioma treatment
• Market Restraints
  • High cost of malignant mesothelioma surgical treatment
• Market Opportunities
  • Introduction of novel therapies for the treatment of malignant mesothelioma
  • Favorable funding landscape for research on malignant mesothelioma
• Market Challenges
  • Adverse effects associated with the treatment of malignant mesothelioma

Porter's Five Forces: A Strategic Tool for Navigating the Malignant Mesothelioma Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Malignant Mesothelioma Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Malignant Mesothelioma Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Malignant Mesothelioma Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Malignant Mesothelioma Market

A detailed market share analysis in the Malignant Mesothelioma Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Malignant Mesothelioma Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Malignant Mesothelioma Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Malignant Mesothelioma Market

A strategic analysis of the Malignant Mesothelioma Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Malignant Mesothelioma Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Advanz Pharma Corp., Argenx SE, AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories, Eisai Co., Ltd., Eli Lilly and Company, Emcure Pharmaceuticals Limited, F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Karyopharm Therapeutics Inc., Merck & Co., Inc., Mylan N.V., Nichi-Iko Pharmaceutical Co., Ltd., Novartis AG, Novocure GmbH, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Polaris Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceuticals Industries Ltd., and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Malignant Mesothelioma Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Carboplatin, Cisplatin, Gemcitabine, Pemetrexed, and Vinorelbine.
• Based on Treatment Type, market is studied across Chemotherapy, Immunotherapy, and Targeted therapy. The Chemotherapy is further studied across Local Chemotherapy and Systemic Chemotherapy.
• Based on Route of Administration, market is studied across Oral and Parenteral.
• Based on Distribution, market is studied across Hospitals Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence of malignant mesothelioma worldwide
    • 5.1.1.2. Increase in the number of clinical trials for the treatment of malignant mesothelioma
    • 5.1.1.3. Use of diagnostic and prognostic biomarkers for malignant mesothelioma treatment
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of malignant mesothelioma surgical treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of novel therapies for the treatment of malignant mesothelioma
    • 5.1.3.2. Favorable funding landscape for research on malignant mesothelioma
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effects associated with the treatment of malignant mesothelioma
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Malignant Mesothelioma Market, by Drug Type

• 6.1. Introduction
• 6.2. Carboplatin
• 6.3. Cisplatin
• 6.4. Gemcitabine
• 6.5. Pemetrexed
• 6.6. Vinorelbine

7. Malignant Mesothelioma Market, by Treatment Type

• 7.1. Introduction
• 7.2. Chemotherapy
  • 7.2.1. Local Chemotherapy
  • 7.2.2. Systemic Chemotherapy
• 7.3. Immunotherapy
• 7.4. Targeted therapy

8. Malignant Mesothelioma Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral

9. Malignant Mesothelioma Market, by Distribution

• 9.1. Introduction
• 9.2. Hospitals Pharmacies
• 9.3. Online Pharmacies
• 9.4. Retail Pharmacies

10. Americas Malignant Mesothelioma Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Malignant Mesothelioma Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Malignant Mesothelioma Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Advanz Pharma Corp.
• 3. Argenx SE
• 4. AstraZeneca Plc
• 5. Boehringer Ingelheim GmbH
• 6. Bristol-Myers Squibb Company
• 7. Cipla Limited
• 8. Dr. Reddy's Laboratories
• 9. Eisai Co., Ltd.
• 10. Eli Lilly and Company
• 11. Emcure Pharmaceuticals Limited
• 12. F. Hoffmann-La Roche Ltd.
• 13. Fresenius Kabi AG
• 14. Karyopharm Therapeutics Inc.
• 15. Merck & Co., Inc.
• 16. Mylan N.V.
• 17. Nichi-Iko Pharmaceutical Co., Ltd.
• 18. Novartis AG
• 19. Novocure GmbH
• 20. Ono Pharmaceutical Co. Ltd.
• 21. Pfizer Inc.
• 22. Polaris Pharmaceuticals, Inc.
• 23. Sanofi S.A.
• 24. Sun Pharmaceuticals Industries Ltd.
• 25. Wellona Pharma